Syndax Pharmaceuticals, Inc. SNDX

SNDX Company Overview

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company operates within the biopharmaceutical and oncology industries, with a primary emphasis on hematologic malignancies and genetically defined cancers. Syndax’s strategy centers on targeting cancer biology through epigenetic modulation and precision oncology approaches.

The company’s principal revenue driver is REVTYRA® (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A rearrangement. In addition to its commercial product, Syndax maintains a development pipeline aimed at addressing high-unmet-need cancer indications. Founded in 2005, the company initially focused on endocrine therapies before pivoting to oncology, later advancing epigenetic programs that reshaped its long-term strategy and led to its transition into a commercial-stage enterprise.